BDTX
Black Diamond Therapeutics, Inc.
Price Chart
Latest Quote
$1.67
-0.01 (-0.60%)
Current Price
| Previous Close | $1.68 |
| Open | $1.70 |
| Day High | $1.75 |
| Day Low | $1.64 |
| Volume | 1,731,115 |
Stock Information
| Shares Outstanding | 57.30M |
| Total Debt | $17.88M |
| Cash Equivalents | $118.26M |
| Net Income | $-43.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $95.69M |
| EPS (TTM) | $-0.77 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.11M |
| Income | $-43.21M |
| Book/sh | $1.82 |
| Cash/sh | $2.06 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 8.14 |
| Current Ratio | 8.46 |
| Debt/Eq | 17.14 |
Returns & Margins
| ROA | -18.57% |
| ROE | -35.16% |
Ownership
| Insider Ownership | 0.62% |
| Institutional Ownership | 78.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.44 |
| P/B | 0.92 |
Analyst Data
| Recommendation | none |
| Target Price | $9.86 |
Technical Indicators
| SMA20 | $2.17 |
| SMA50 | $2.56 |
| SMA200 | $2.89 |
| RSI | 11.84 |
| ATR | 0.1291 |
| Shares Float | 52.44M |
| Short Float | 15.15% |
| Short Ratio | 3.02 |
| Volatility | 3.23 |
| Rel Volume | 0.72 |
Performance History
| Week | -9.73% |
| Month | -35.27% |
| Quarter | -23.04% |
| 6 Months | -36.98% |
| YTD | -32.93% |
| Year | -30.13% |
| 3 Years | -18.93% |
| 5 Years | -86.81% |
| 10 Years | -95.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $1.67 | 1,733,200 |
| 2026-06-16 | $1.68 | 1,867,400 |
| 2026-06-15 | $1.72 | 2,206,200 |
| 2026-06-12 | $1.75 | 2,312,300 |
| 2026-06-11 | $1.82 | 1,446,100 |
| 2026-06-10 | $1.85 | 1,549,700 |
| 2026-06-09 | $1.90 | 1,719,900 |
| 2026-06-08 | $1.85 | 1,114,100 |
| 2026-06-05 | $1.97 | 1,022,700 |
| 2026-06-04 | $2.09 | 632,200 |
| 2026-06-03 | $2.10 | 848,700 |
| 2026-06-02 | $2.18 | 1,373,200 |
| 2026-06-01 | $2.26 | 994,300 |
| 2026-05-29 | $2.22 | 2,165,800 |
| 2026-05-28 | $2.25 | 1,197,600 |
| 2026-05-27 | $2.31 | 1,895,000 |
| 2026-05-26 | $2.33 | 2,676,400 |
| 2026-05-22 | $2.28 | 8,382,100 |
| 2026-05-21 | $3.55 | 5,286,100 |
| 2026-05-20 | $3.60 | 7,943,200 |
| 2026-05-19 | $3.00 | 1,898,800 |
| 2026-05-18 | $2.58 | 678,500 |
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
MarketBeat âĸ 2026-06-06T09:04:54Z
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Zacks âĸ 2026-05-27T15:16:00Z
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Zacks âĸ 2026-05-27T15:13:00Z
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Zacks âĸ 2026-05-27T15:10:00Z
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Zacks âĸ 2026-05-25T14:53:00Z
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
MarketBeat âĸ 2026-05-21T23:09:11Z
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Zacks âĸ 2026-05-11T15:48:00Z
Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2026-05-11T11:54:52Z
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
Zacks âĸ 2026-04-28T11:05:00Z
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Zacks âĸ 2026-04-23T15:29:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $70,000,000 | $0 | $0 | $0 |
| Operating Revenue | $70,000,000 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $50,130,000 | $78,781,000 | $86,460,000 | $92,828,000 |
| Other Income Expense | $-1,564,000 | $6,923,000 | $2,094,000 | $-372,000 |
| Other Non Operating Income Expenses | $5,784,000 | $6,923,000 | $2,094,000 | $-354,000 |
| Net Non Operating Interest Income Expense | $4,061,000 | $2,182,000 | $1,924,000 | $2,031,000 |
| Operating Expense | $50,130,000 | $78,781,000 | $86,460,000 | $92,828,000 |
| General And Administrative Expense | $16,572,000 | $27,469,000 | $27,110,000 | $28,391,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Net Interest Income | $4,061,000 | $2,182,000 | $1,924,000 | $2,031,000 |
| Interest Income | $4,061,000 | $2,182,000 | $1,924,000 | $2,031,000 |
| Normalized Income | $29,715,000 | $-69,676,000 | $-82,442,000 | $-93,401,000 |
| Net Income From Continuing And Discontinued Operation | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Total Operating Income As Reported | $12,522,000 | $-78,781,000 | $-86,460,000 | $-92,828,000 |
| Net Income Common Stockholders | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Net Income | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Net Income Including Noncontrolling Interests | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Net Income Continuous Operations | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Pretax Income | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Special Income Charges | $-7,348,000 | $0 | $0 | $2,232,000 |
| Interest Income Non Operating | $4,061,000 | $2,182,000 | $1,924,000 | $2,031,000 |
| Operating Income | $19,870,000 | $-78,781,000 | $-86,460,000 | $-92,828,000 |
| Earnings From Equity Interest | - | - | $0 | $-2,250,000 |
| Per Share | ||||
| Diluted EPS | $0.39 | $-1.27 | $-1.88 | $-2.52 |
| Basic EPS | $0.39 | $-1.27 | $-1.88 | $-2.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $27,543,000 | $-78,438,000 | $-86,023,000 | $-94,552,000 |
| Total Unusual Items | $-7,348,000 | $0 | $0 | $2,232,000 |
| Total Unusual Items Excluding Goodwill | $-7,348,000 | $0 | $0 | $2,232,000 |
| Reconciled Depreciation | $325,000 | $343,000 | $437,000 | $508,000 |
| EBITDA (Bullshit earnings) | $20,195,000 | $-78,438,000 | $-86,023,000 | $-92,320,000 |
| EBIT | $19,870,000 | $-78,781,000 | $-86,460,000 | $-92,828,000 |
| Diluted Average Shares | $57,562,746 | $55,028,371 | $43,954,649 | $36,229,809 |
| Basic Average Shares | $56,868,111 | $55,028,371 | $43,954,649 | $36,229,809 |
| Diluted NI Availto Com Stockholders | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Impairment Of Capital Assets | $7,348,000 | $0 | - | - |
| Research And Development | $33,558,000 | $51,312,000 | $59,350,000 | $64,437,000 |
| Selling General And Administration | $16,572,000 | $27,469,000 | $27,110,000 | $28,391,000 |
| Other Gand A | $16,572,000 | $27,469,000 | $27,110,000 | $28,391,000 |
| Gain On Sale Of Ppe | - | - | $0 | $2,232,000 |
Fetched: 2026-06-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Total Assets | $143,010,000 | $122,640,000 | $158,567,000 | $156,255,000 |
| Total Non Current Assets | $10,570,000 | $21,464,000 | $24,533,000 | $28,549,000 |
| Other Non Current Assets | $902,000 | $1,068,000 | $823,000 | $1,168,000 |
| Current Assets | $132,440,000 | $101,176,000 | $134,034,000 | $127,706,000 |
| Other Current Assets | $3,788,000 | $2,601,000 | $2,634,000 | $4,899,000 |
| Cash Cash Equivalents And Short Term Investments | $128,652,000 | $98,575,000 | $131,400,000 | $122,807,000 |
| Cash And Cash Equivalents | $20,990,000 | $36,437,000 | $56,221,000 | $34,315,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $18,781,000 | $22,186,000 | $25,298,000 | $28,140,000 |
| Long Term Debt And Capital Lease Obligation | $15,068,000 | $18,782,000 | $22,185,000 | $25,299,000 |
| Current Debt And Capital Lease Obligation | $3,713,000 | $3,404,000 | $3,113,000 | $2,841,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $30,799,000 | $39,355,000 | $41,831,000 | $40,560,000 |
| Total Non Current Liabilities Net Minority Interest | $15,068,000 | $18,782,000 | $22,185,000 | $25,299,000 |
| Current Liabilities | $15,731,000 | $20,573,000 | $19,646,000 | $15,261,000 |
| Payables And Accrued Expenses | $12,018,000 | $17,169,000 | $16,533,000 | $12,420,000 |
| Payables | $579,000 | $4,007,000 | $2,324,000 | $1,877,000 |
| Accounts Payable | $579,000 | $4,007,000 | $2,324,000 | $1,877,000 |
| Equity | ||||
| Common Stock Equity | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Total Equity Gross Minority Interest | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Stockholders Equity | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Gains Losses Not Affecting Retained Earnings | $101,000 | $24,000 | $-27,000 | $-1,824,000 |
| Other Equity Adjustments | $101,000 | $24,000 | $-27,000 | $-1,824,000 |
| Retained Earnings | $-464,740,000 | $-487,107,000 | $-417,431,000 | $-334,989,000 |
| Other | ||||
| Ordinary Shares Number | $57,138,057 | $56,644,655 | $51,645,557 | $36,434,297 |
| Share Issued | $57,138,057 | $56,644,655 | $51,645,557 | $36,434,297 |
| Tangible Book Value | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Invested Capital | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Working Capital | $116,709,000 | $80,603,000 | $114,388,000 | $112,445,000 |
| Capital Lease Obligations | $18,781,000 | $22,186,000 | $25,298,000 | $28,140,000 |
| Total Capitalization | $112,211,000 | $83,285,000 | $116,736,000 | $115,695,000 |
| Additional Paid In Capital | $576,842,000 | $570,361,000 | $534,187,000 | $452,503,000 |
| Capital Stock | $8,000 | $7,000 | $7,000 | $5,000 |
| Common Stock | $8,000 | $7,000 | $7,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $15,068,000 | $18,782,000 | $22,185,000 | $25,299,000 |
| Current Capital Lease Obligation | $3,713,000 | $3,404,000 | $3,113,000 | $2,841,000 |
| Current Accrued Expenses | $11,439,000 | $13,162,000 | $14,209,000 | $10,543,000 |
| Net PPE | $9,668,000 | $20,396,000 | $23,710,000 | $27,381,000 |
| Accumulated Depreciation | $-1,228,000 | $-1,142,000 | $-799,000 | $-750,000 |
| Gross PPE | $10,896,000 | $21,538,000 | $24,509,000 | $28,131,000 |
| Leases | $1,593,000 | $2,512,000 | $2,512,000 | $2,512,000 |
| Other Properties | $9,303,000 | $19,009,000 | $21,980,000 | $25,564,000 |
| Machinery Furniture Equipment | $0 | $17,000 | $17,000 | $55,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $107,662,000 | $62,138,000 | $75,179,000 | $88,492,000 |
| Construction In Progress | - | - | - | $0 |
Fetched: 2026-06-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $29,614,000 | $-62,303,000 | $-66,750,000 | $-85,274,000 |
| Operating Activities | ||||
| Operating Cash Flow | $29,614,000 | $-62,303,000 | $-66,717,000 | $-85,082,000 |
| Cash Flow From Continuing Operating Activities | $29,614,000 | $-62,303,000 | $-66,717,000 | $-85,082,000 |
| Operating Gains Losses | $7,247,000 | $-94,000 | $358,000 | $17,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-44,905,000 | $16,968,000 | $16,346,000 | $53,366,000 |
| Cash Flow From Continuing Investing Activities | $-44,905,000 | $16,968,000 | $16,346,000 | $53,366,000 |
| Capital Expenditure | - | - | $-33,000 | $-192,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $24,494,000 | $71,850,000 | $0 |
| Financing Cash Flow | $-146,000 | $25,547,000 | $71,932,000 | $177,000 |
| Cash Flow From Continuing Financing Activities | $-146,000 | $25,547,000 | $71,932,000 | $177,000 |
| Net Common Stock Issuance | $0 | $24,494,000 | $71,850,000 | $0 |
| Common Stock Issuance | $0 | $24,494,000 | $71,850,000 | $0 |
| Other | ||||
| End Cash Position | $21,819,000 | $37,256,000 | $57,044,000 | $35,483,000 |
| Beginning Cash Position | $37,256,000 | $57,044,000 | $35,483,000 | $67,022,000 |
| Changes In Cash | $-15,437,000 | $-19,788,000 | $21,561,000 | $-31,539,000 |
| Proceeds From Stock Option Exercised | $-146,000 | $1,053,000 | $82,000 | $177,000 |
| Net Investment Purchase And Sale | $-44,932,000 | $16,874,000 | $16,284,000 | $53,549,000 |
| Sale Of Investment | $119,094,000 | $139,750,000 | $78,171,000 | $113,690,000 |
| Purchase Of Investment | $-164,026,000 | $-122,876,000 | $-61,887,000 | $-60,141,000 |
| Net PPE Purchase And Sale | $27,000 | $94,000 | $62,000 | $-183,000 |
| Sale Of PPE | $27,000 | $94,000 | $95,000 | $9,000 |
| Change In Working Capital | $-8,728,000 | $-2,692,000 | $3,686,000 | $-9,901,000 |
| Change In Other Current Liabilities | $-3,713,000 | $-3,403,000 | $-3,114,000 | $-2,841,000 |
| Change In Other Current Assets | $176,000 | $-249,000 | $0 | $16,000 |
| Change In Payables And Accrued Expense | $-4,842,000 | $927,000 | $4,535,000 | $-8,094,000 |
| Change In Accrued Expense | $-1,414,000 | $-756,000 | $3,938,000 | $-5,864,000 |
| Change In Payable | $-3,428,000 | $1,683,000 | $597,000 | $-2,230,000 |
| Change In Account Payable | $-3,428,000 | $1,683,000 | $597,000 | $-2,230,000 |
| Change In Prepaid Assets | $-349,000 | $33,000 | $2,265,000 | $1,018,000 |
| Other Non Cash Items | $3,054,000 | $2,971,000 | $2,814,000 | $2,730,000 |
| Stock Based Compensation | $6,628,000 | $10,627,000 | $9,604,000 | $12,197,000 |
| Amortization Of Securities | $-1,279,000 | $-3,782,000 | $-1,174,000 | $536,000 |
| Depreciation Amortization Depletion | $325,000 | $343,000 | $437,000 | $508,000 |
| Depreciation And Amortization | $325,000 | $343,000 | $437,000 | $508,000 |
| Depreciation | $325,000 | $343,000 | $437,000 | $508,000 |
| Gain Loss On Investment Securities | $-74,000 | - | - | - |
| Gain Loss On Sale Of PPE | $7,321,000 | $-94,000 | $358,000 | $-2,233,000 |
| Net Income From Continuing Operations | $22,367,000 | $-69,676,000 | $-82,442,000 | $-91,169,000 |
| Purchase Of PPE | - | $0 | $-33,000 | $-192,000 |
| Earnings Losses From Equity Investments | - | - | $0 | $2,250,000 |
Fetched: 2026-06-10